Form 4 holding
Chief Scientific Officer, Director
Monopar Therapeutics
- Security class
- Common Stock
- Shares / value
- 166,667
- Estimated value
- $56,700
- Report date
- 31 Mar 2022
- Price
- $0.3402
- Ownership
- Indirect
Andrew Paul Mazar
Insider Reports History
- Reporting-owner location
- Fort Worth, TX
- Latest reporting-owner signature
-
/s/ Paul Lytle, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Andrew Paul Mazar
Form 4 holding
Chief Scientific Officer, Director
Monopar Therapeutics
- Security class
- Restricted Stock Units
- Shares / value
- 88,792
- Estimated value
- $30,207
- Report date
- 31 Mar 2022
- Price
- $0.3402
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Scientific Officer, Director
Monopar Therapeutics
- Security class
- Common Stock
- Shares / value
- 22,125
- Estimated value
- $7,527
- Report date
- 31 Mar 2022
- Price
- $0.3402
- Ownership
- Direct
Form 4 holding
Chief Operating Officer
ACTUATE THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 127,250
- Estimated value
- Report date
- 12 Aug 2024
- Price
- Ownership
- Direct
Form 4 holding
Chief Operating Officer
ACTUATE THERAPEUTICS, INC.
- Security class
- Employee Stock Option (right to buy)
- Shares / value
- 105,000
- Estimated value
- Report date
- 01 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Andrew Paul Mazar
4
ACTU
ACTUATE THERAPEUTICS, INC.
- Report period
- 01 Apr 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2026, 17:19
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
ACTU
ACTUATE THERAPEUTICS, INC.
- Report period
- 01 Apr 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Apr 2025, 13:43
- Role
- Chief Operating Officer
- Next action
- Open filing details
3
ACTU
ACTUATE THERAPEUTICS, INC.
- Report period
- 12 Aug 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 12 Aug 2024, 21:47
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 31 Mar 2022
- Transactions
- 3
- Transaction value
- -$1,201
- Accepted by SEC
- 01 Apr 2022, 17:28
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 02 Feb 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 04 Feb 2022, 18:38
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 01 Jan 2022
- Transactions
- 3
- Transaction value
- -$2,154
- Accepted by SEC
- 04 Jan 2022, 13:49
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 31 Dec 2021
- Transactions
- 3
- Transaction value
- -$1,785
- Accepted by SEC
- 04 Jan 2022, 13:40
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 30 Sep 2021
- Transactions
- 3
- Transaction value
- -$2,294
- Accepted by SEC
- 01 Oct 2021, 19:31
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details
4
MNPR
Monopar Therapeutics
- Report period
- 30 Jun 2021
- Transactions
- 3
- Transaction value
- -$5,548
- Accepted by SEC
- 02 Jul 2021, 17:11
- Role
- Chief Scientific Officer, Director
- Next action
- Open filing details